Kurzporträt
Umsatz nach Geschäftsbereich
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Placenta-Based Cell Therapy
100,0
%
| 0 | 100,0 % | 0 | 100,0 % | +22.65% |
Umsatz je Region
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Israel
100,0
%
| 0 | 100,0 % | 0 | 100,0 % | +22.65% |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Yaky Yanay
CEO | Chief Executive Officer | 52 | 01.11.06 |
Director of Finance/CFO | 40 | 01.05.13 | |
Zami Aberman
CHM | Chairman | 70 | 26.09.05 |
Artur Machlenkin
CTO | Chief Tech/Sci/R&D Officer | - | 01.05.22 |
Nitsan Halevy
CTO | Chief Tech/Sci/R&D Officer | - | 01.03.21 |
Lior Raviv
CTO | Chief Tech/Sci/R&D Officer | - | 01.01.11 |
Orly Amiran
PRN | Corporate Officer/Principal | - | - |
Nimrod Bar Zvi
PRN | Corporate Officer/Principal | - | - |
Efrat Kaduri
PRN | Corporate Officer/Principal | - | 01.10.14 |
Human Resources Officer | 62 | 01.01.07 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Director/Board Member | 73 | 15.07.21 | |
Lorne Abony
BRD | Director/Board Member | 55 | 11.07.23 |
Zami Aberman
CHM | Chairman | 70 | 26.09.05 |
Yaky Yanay
CEO | Chief Executive Officer | 52 | 01.11.06 |
Director/Board Member | 54 | 06.01.21 | |
Director/Board Member | 61 | 01.06.21 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 5 388 792 | 4 101 934 ( 76,12 %) | 0 | 76,12 % |
Unternehmenskontakt
Pluri, Inc.
MATAM Advanced Technology Park Building No. 5
3508409, Haifa
+972 74 710 8600
http://www.pluri-biotech.comSektor
% 1. Jan. | Kap. | |
---|---|---|
+22.71% | 47.9 Mrd. | |
+46.56% | 41.42 Mrd. | |
-2.01% | 40.7 Mrd. | |
-6.20% | 28.92 Mrd. | |
+9.88% | 25.55 Mrd. | |
-21.29% | 19.27 Mrd. | |
-0.06% | 12.15 Mrd. | |
+29.21% | 12.14 Mrd. | |
-0.66% | 11.99 Mrd. |